Repros’ Proellex Is Poised To Enter Phase III – Again
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Telapristone was put on clinical hold due to liver toxicity, but the company’s pursuit of vaginal formulation and re-analysis of the initial oral studies allowed the oral program to resume.